Cwm LLC Raises Holdings in Agilent Technologies, Inc. (NYSE:A)

Cwm LLC lifted its stake in Agilent Technologies, Inc. (NYSE:A) by 12.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,559 shares of the medical research company’s stock after buying an additional 836 shares during the quarter. Cwm LLC’s holdings in Agilent Technologies were worth $1,051,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of A. OFI Invest Asset Management acquired a new position in Agilent Technologies in the 3rd quarter worth about $25,000. MV Capital Management Inc. raised its holdings in Agilent Technologies by 120.7% in the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares during the period. Baystate Wealth Management LLC raised its holdings in Agilent Technologies by 107.3% in the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after purchasing an additional 133 shares during the period. Column Capital Advisors LLC raised its holdings in Agilent Technologies by 1,111.1% in the 3rd quarter. Column Capital Advisors LLC now owns 327 shares of the medical research company’s stock worth $37,000 after purchasing an additional 300 shares during the period. Finally, Rosenberg Matthew Hamilton raised its holdings in Agilent Technologies by 51.1% in the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares during the period.

Insider Activity

In other news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the transaction, the director now owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, SVP Philip Binns sold 2,827 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the sale, the senior vice president now directly owns 9,997 shares in the company, valued at approximately $1,474,957.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the sale, the director now owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The disclosure for this sale can be found here. Insiders sold 61,610 shares of company stock worth $9,220,333 over the last ninety days.

Analyst Ratings Changes

A number of equities analysts recently weighed in on A shares. Barclays upped their price target on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Citigroup increased their target price on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. UBS Group increased their target price on Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Oppenheimer increased their price target on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Finally, Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and increased their price target for the company from $145.00 to $163.00 in a report on Friday, April 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $141.29.

Agilent Technologies Stock Up 1.0 %

Agilent Technologies stock opened at $137.74 on Friday. The company has a market capitalization of $40.36 billion, a P/E ratio of 32.80, a PEG ratio of 4.13 and a beta of 1.11. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.04 and a current ratio of 2.68. The stock has a 50-day simple moving average of $141.59 and a 200-day simple moving average of $130.68. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $151.58.

Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the prior year, the company earned $1.37 EPS. Agilent Technologies’s revenue was down 5.5% on a year-over-year basis. Equities research analysts expect that Agilent Technologies, Inc. will post 5.5 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were paid a dividend of $0.236 per share. The ex-dividend date of this dividend was Monday, April 1st. This represents a $0.94 annualized dividend and a dividend yield of 0.69%. Agilent Technologies’s dividend payout ratio is presently 22.38%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.